A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. - Wikidata - wikimedia - TriplyDB

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

http://www.wikidata.org/entity/Q35837764

about

High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway Targeted therapies in CLL: mechanisms of resistance and strategies for management Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes The phosphoinositide 3-kinase pathway and therapy resistance in cancer Mapping the Pathways of Resistance to Targeted Therapies PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics ERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signaling Chemogenomics and orthology-based design of antibiotic combination therapies MYC on the path to cancer Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors.High-resolution network biology: connecting sequence with function.TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens.Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.PTEN action in leukaemia dictated by the tissue microenvironment.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers Myc-dependent genome instability and lifespan in Drosophila.MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers Systematic identification of signaling pathways with potential to confer anticancer drug resistance.PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction.Emerging therapeutics targeting mRNA translation Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.Metformin inhibits salivary adenocarcinoma growth through cell cycle arrest and apoptosis Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.eIF4F suppression in breast cancer affects maintenance and progression Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition

P2860

Q23058134-C09DE63A-4BD0-4217-A622-CE87DA185003 Q26825780-E2F604F8-87E2-4ACA-BF87-F827F0E50640 Q27002528-6C57412B-8AE0-4D7F-B498-069ED844ECF5 Q28072745-52596175-FB3D-43DA-BC46-381F988EAA38 Q28082811-DAD3082F-44E7-44FC-864E-1B2227A8B41B Q28088791-12C5F122-672F-4C5D-9002-23D961BBABCF Q28259003-92AA0B3A-55DB-4575-8ABF-9029CCDB42FA Q28484833-3F631906-264D-413F-BB70-92BD0C17C4A4 Q28817589-071CDCF2-1D30-44A4-9FD3-EB8A2F8B9505 Q29619979-E334C183-1AC2-446E-ABF2-291856D97024 Q33571352-19EF0B6A-EB59-452B-B335-EF352900825B Q33623110-2A1609F5-6D57-47FA-8526-73D03BF982E1 Q33828463-03258E0B-E094-4685-88D4-8F6BB4CD509F Q33880093-A9C7A78E-54FE-4A77-B0F7-5BEB32E706AC Q33937368-8AE91E1A-4274-4D67-AB2D-31A4E5139B6F Q34196262-49FCC354-4F32-4029-9367-232207EC5DB2 Q34307356-328B8953-866C-4526-A231-BA3AA3096431 Q34608239-9002EC50-1299-4219-98B4-D40EE23F57FF Q34706060-18AC615A-6A30-45BD-9B20-C5D8BBF67CA2 Q34990194-7ED10159-E686-47D5-89AD-2E68C132B1A5 Q34991267-4DFD0CA7-798A-44A9-80B8-B39CF655D68B Q35159023-716491F9-744B-49A5-B9F5-AB574225767E Q35260766-4AA0593B-F1EA-4380-B239-F8A006526C91 Q35531740-0FC2C795-35DA-41D3-A996-2A9B4FC90839 Q35612277-FE93EAE2-BBBB-4A4C-B6A5-ED6459250DB7 Q35853794-C9487D54-0478-4FD0-A9B8-D997CA90C1BE Q36206219-4521A1A2-B9F2-4799-8C71-110248A6ABC1 Q36516580-CDE277D9-DD00-4CAF-93B8-6FDE5448BE83 Q36765341-901F9190-FFE5-433E-ACA8-A2961851D127 Q36782224-A3089E93-34EC-4D1A-95F9-451478524961 Q36891050-EA239C1C-13DE-4481-8FCA-60CF479D02BA Q36892399-E83A2E12-0AF2-4DFE-B6E3-ACD949E03945 Q36939783-C0168953-4375-4045-98DA-756A99A8A34B Q37031949-503123FD-5A6C-405B-8CBD-CB7154CE0A28 Q37139435-55A67B3C-3E2F-4BCA-A69D-10FFCE0BF96E Q37339881-28CA0E53-E07A-4315-9606-AD7691C0D0DE Q37341834-055A2B6A-DA6A-4401-BB41-8B3559EE6A26 Q37354089-59C68828-2E0B-4068-BD48-783DF371904C Q37605004-9D3E81DB-F836-4571-B284-0597981E422D Q37716027-759A4E61-6A18-4B73-94D9-C7CCE8296275

P2860

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

http://www.wikidata.org/entity/Q35837764

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

@ast

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

@en

type

label

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

@ast

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

@en

prefLabel

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

@ast

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.

@en

P1433

Q35837764-EBD5B398-1575-48DD-9B45-7A2A2E7EC432

P1476

Q35837764-554850FC-099B-4DA7-A173-685AEF2B1CB6

P2093

Q35837764-66675CCA-5430-4A80-80BC-87BC01381E3D

Q35837764-96B68500-B73F-42C5-8F87-493B132BFD46

Q35837764-AEF3CEA7-D7DF-4981-AD33-4F17EC27D22A

Q35837764-B2A76095-322C-4C29-AFD5-BA99AD7B3F29

Q35837764-D0FBDA87-D99C-4E14-9D3E-5F72BA63AC66

Q35837764-D1AD56E2-6454-4E37-BE09-1B53CD7E996A

P2860

Q35837764-011D4D6A-B4B8-40BB-9B1C-DABDCD818A57

Q35837764-055453CC-32BB-48A2-A116-59347B48BBFB

Q35837764-0C5CF476-ED3A-4E53-BEEC-B4EA8069475C

Q35837764-0D7B24DB-084A-4382-8207-C2110509F22B

Q35837764-133B0A8A-F989-4D3C-B245-51E3A44DED9D

Q35837764-15AC12C7-CA93-4932-8BCC-DE9B40B64C92

Q35837764-28557817-7250-4868-B3BB-C2C02C0FB8B5

Q35837764-2FD5F206-A0E4-4D86-99B9-FE0848DAFBD2

Q35837764-3921B1D9-675B-494A-B8DD-32EFF179C373

Q35837764-3CF8D8A0-9520-4B7E-B148-866667FE691D

P2888

Q35837764-B2B801CF-8EAA-456D-8C72-0EA19E9B2014

P304

Q35837764-56D3B4DE-34B8-4B84-811E-BB6D797DD729

P31

Q35837764-250A5DFB-750A-4271-8CC6-A434A93E83C9

P356

Q35837764-4C224313-811A-4352-84B0-FC49BCA58B78

P433

Q35837764-2B2D23DE-A06E-4477-A571-511AF2A25A0D

P478

Q35837764-D2F90D7B-FD3C-43B1-9F66-BD7FAED74495

P50

Q35837764-08612B23-7724-416A-842D-49C10438821C

Q35837764-0E0EE053-4FFF-49DC-AFB8-1EE1B7895A1D

Q35837764-5A50F581-9124-4496-927A-FC75BEA2E37A

Q35837764-EEA79062-4A30-467C-8884-59905CA47CFE

P577

Q35837764-4B5BEBF0-5EDB-487B-93DD-BF7B87B9AB88

P5875

Q35837764-4962BDE1-D85E-4B9A-A2A4-BEB0348615C1

P698

Q35837764-C53FD89A-4812-4807-B952-F32097E207BD

P932

Q35837764-45E819F4-7307-40C0-BF17-E9142FD1FA69

P356

P1433

Nature Chemical Biology

P1476

A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer

@en

P2093

Bianca V Gapp

http://www.w3.org/2001/XMLSchema#string

Claudia Kerzendorfer

http://www.w3.org/2001/XMLSchema#string

Gerhard Duernberger

http://www.w3.org/2001/XMLSchema#string

Hannelore Lechtermann

http://www.w3.org/2001/XMLSchema#string

Markus K Muellner

http://www.w3.org/2001/XMLSchema#string

Nils Craig-Mueller

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Initial impact of the sequencing of the human genome

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

MicroRNA expression profiles classify human cancers

Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway

P2888

P304

787-793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEMBIO.695

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Sebastian Nijman

Jacques Colinge

P577

2011-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51673357

http://www.w3.org/2001/XMLSchema#string

P698

21946274

http://www.w3.org/2001/XMLSchema#string

P932

3306898

http://www.w3.org/2001/XMLSchema#string